Patients with microsatellite-unstable gastric adenocarcinoma cannot benefit from chemotherapy, According to the guideline of the Chinese Society of Clinical Oncology, It is not recommended to receive chemotherapy for patients with microsatellite-unstable gastric cancer, therefore, immunotherapy is the only hope for those patients.
Our study is aim to evaluate the efficacy and safety of pabolizumab in neoadjuvant immunotherapy of locally advanced microsatellite-unstable gastric adenocarcinoma.